Benzinga | Mar 31, 2021 06:33AM EDT

BMO Capital Initiates Coverage On C4 Therapeutics with Outperform Rating, Announces Price Target of $55

BMO Capital analyst Matthew Luchini initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Outperform rating and announces Price Target of $55.